Outlining Risk Factor Identification and Mitigation in Bladder Cancer

Commentary
Video

Ongoing research suggests environmental exposures and the role of microbiomes may influence bladder cancer development and response to treatment.

CancerNetwork® spoke with Armine K. Smith, MD, assistant professor of Urology and director of Urologic Oncology at Sibley Memorial Hospital, part of Johns Hopkins Medicine, about risk factors related to bladder cancer, as well as approaches to help mitigate them.

Smith initially touched upon well-established risk factors, identifying smoking, exposure to chemicals used in dye and rubber industries, and chronic bladder inflammation as the most common risk factors. Additionally, she explained that a minority of patients have a genetic predisposition to forming bladder tumors as well.

She then outlined some preventative measures patients can take to mitigate the risk of bladder cancer, including smoking cessation or abstention, minimizing chemical exposure, and the presence and utilization of a program for early detection of bladder cancers, particularly among patients at a higher risk for developing the disease.

Smith further expressed that ongoing research is seeking to elucidate whether other environmental exposures, which are not typically associated with bladder cancer risk, may actually impact the development of the disease. Finally, she stated that research may also uncover the role of microbiomes in the development of bladder tumors and their response to treatment.

Transcript:

To even summarize, there are well-established risk factors, such as smoking, exposure to some chemicals that are used in the dye and rubber industries, chronic bladder inflammation, [and] there is a minority of patients who have a genetic predisposition to forming bladder tumors. Preventative measures include smoking cessation, or never smoking, if possible, minimizing chemical exposures when possible, and then having a program for detecting these cancers earlier and [for] patients at risk.

Ongoing research also suggests there might be some other environmental exposures that are not usually associated with bladder cancer and more information to come, [as well as] the role of microbiome in developing these cancers and responses to the treatments for these cancers.

Recent Videos
Patients with AML will experience different toxicities based on the treatment they receive, whether it is intensive chemotherapy or targeted therapy.
A younger patient with AML who is more fit may be eligible for different treatments than an older patient with chronic medical conditions.
Breast cancer care providers make it a goal to manage the adverse effects that patients with breast cancer experience to minimize the burden of treatment.
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Genetic backgrounds and ancestry may hold clues for better understanding pancreatic cancer, which may subsequently mitigate different disparities.
Factors like genetic mutations and smoking may represent red flags in pancreatic cancer detection, said Jose G. Trevino, II, MD, FACS.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
Numerous clinical trials vindicating the addition of immunotherapy to first-line chemotherapy in SCLC have emerged over the last several years.
According to John Henson, MD, “What we need are better treatments to control the [brain] tumor once it’s detected.”
First-degree relatives of patients who passed away from pancreatic cancer should be genetically tested to identify their risk for the disease.
Related Content